Indiana University School of Medicine, Indianapolis, IN, USA.
Isparta University of Applied Sciences, Isparta, Turkey.
Genome Biol. 2022 May 11;23(1):113. doi: 10.1186/s13059-022-02677-z.
Colorectal cancer (CRC) consensus molecular subtypes (CMS) have different immunological, stromal cell, and clinicopathological characteristics. Single-cell characterization of CMS subtype tumor microenvironments is required to elucidate mechanisms of tumor and stroma cell contributions to pathogenesis which may advance subtype-specific therapeutic development. We interrogate racially diverse human CRC samples and analyze multiple independent external cohorts for a total of 487,829 single cells enabling high-resolution depiction of the cellular diversity and heterogeneity within the tumor and microenvironmental cells.
Tumor cells recapitulate individual CMS subgroups yet exhibit significant intratumoral CMS heterogeneity. Both CMS1 microsatellite instability (MSI-H) CRCs and microsatellite stable (MSS) CRC demonstrate similar pathway activations at the tumor epithelial level. However, CD8+ cytotoxic T cell phenotype infiltration in MSI-H CRCs may explain why these tumors respond to immune checkpoint inhibitors. Cellular transcriptomic profiles in CRC exist in a tumor immune stromal continuum in contrast to discrete subtypes proposed by studies utilizing bulk transcriptomics. We note a dichotomy in tumor microenvironments across CMS subgroups exists by which patients with high cancer-associated fibroblasts (CAFs) and C1Q+TAM content exhibit poor outcomes, providing a higher level of personalization and precision than would distinct subtypes. Additionally, we discover CAF subtypes known to be associated with immunotherapy resistance.
Distinct CAFs and C1Q+ TAMs are sufficient to explain CMS predictive ability and a simpler signature based on these cellular phenotypes could stratify CRC patient prognosis with greater precision. Therapeutically targeting specific CAF subtypes and C1Q + TAMs may promote immunotherapy responses in CRC patients.
结直肠癌(CRC)共识分子亚型(CMS)具有不同的免疫学、基质细胞和临床病理特征。需要对 CMS 亚型肿瘤微环境进行单细胞特征分析,以阐明肿瘤和基质细胞对发病机制的贡献机制,这可能会推进针对特定亚型的治疗方法的发展。我们对不同种族的 CRC 样本进行了检测,并对多个独立的外部队列进行了分析,总共对 487,829 个单细胞进行了分析,从而可以高分辨率地描绘肿瘤和微环境细胞内的细胞多样性和异质性。
肿瘤细胞再现了个体 CMS 亚组,但表现出显著的肿瘤内 CMS 异质性。CMS1 微卫星不稳定(MSI-H)CRC 和微卫星稳定(MSS)CRC 在肿瘤上皮水平均表现出相似的通路激活。然而,MSI-H CRC 中 CD8+细胞毒性 T 细胞表型浸润可能解释了为什么这些肿瘤对免疫检查点抑制剂有反应。CRC 的细胞转录组谱在肿瘤免疫基质连续体中存在,而不是在利用批量转录组学研究提出的离散亚型中存在。我们注意到 CMS 亚组之间的肿瘤微环境存在二分法,即具有高癌症相关成纤维细胞(CAF)和 C1Q+TAM 含量的患者预后不良,这比离散亚型提供了更高水平的个性化和精准性。此外,我们发现了与免疫治疗耐药性相关的 CAF 亚型。
不同的 CAF 和 C1Q+TAM 足以解释 CMS 的预测能力,并且基于这些细胞表型的更简单的特征可以更精确地分层 CRC 患者的预后。针对特定的 CAF 亚型和 C1Q+TAM 进行治疗可能会促进 CRC 患者的免疫治疗反应。